PMID: 7028243Nov 15, 1981Paper

Bone marrow transplantation for acute myelosclerosis

Cancer
J W SmithC D Buckner

Abstract

Four patients with acute myelosclerosis were treated with chemoradiotherapy and bone marrow transplantation. Three of the four had prompt engraftment with greater than 0.10 X 10(9) granulocytes/liter three weeks after transplantation. One patient continues in complete remission one year after transplantation. One patient experienced a partial remission and two patients died early in the post-transplantation period. Marrow fibrosis disappeared in three of the four patients. The patient with residual marrow fibrosis died 22 days after transplantation. It is apparent that marrow fibrosis is reversible. In view of the absence of other effective therapy, intensive therapy with marrow transplantation should be considered as primary therapy for patients with acute myelosclerosis who have a suitable marrow donor.

References

Sep 1, 1979·Transplantation·R A CliftB W Goodell
Apr 17, 1975·The New England Journal of Medicine·E ThomasC D Buckner
Jun 1, 1977·American Journal of Clinical Pathology·T Bird, S J Proctor
Jan 1, 1979·Cancer·R M BearmanH Rappaport
Jan 1, 1977·Acta Haematologica·E KelemenG Szinay
May 1, 1979·British Journal of Haematology·G J den OttolanderR Bieger
Apr 1, 1977·American Journal of Clinical Pathology·D R Fabich, P C Raich
Nov 1, 1976·Cancer·P NowellJ German
Nov 20, 1976·British Medical Journal·A R PatelH L Rhee
Jan 1, 1968·Acta Haematologica·M H Khan, H Martin
Jul 1, 1971·American Journal of Clinical Pathology·D E Bauermeister
Feb 1, 1969·Archives of Internal Medicine·W J MitusK A Kiossoglou
Jan 1, 1980·American Journal of Clinical Pathology·D D Weisenburger

❮ Previous
Next ❯

Citations

Jan 1, 1993·International Journal of Clinical & Laboratory Research·H C Hasselbalch
Jul 1, 1988·Cancer Genetics and Cytogenetics·S LichtmanM Susin
Aug 1, 1996·Cancer Genetics and Cytogenetics·E F AllenR E Branda
Nov 1, 1985·Human Immunology·E FerreiraR Pasquini
Mar 13, 1982·Lancet·C RozmanR Brugués
Sep 5, 2001·Leukemia Research·D P SteensmaA Tefferi
Oct 1, 1983·Clinics in Haematology·R Storb, G W Santos
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Mar 1, 1993·Leukemia & Lymphoma·H Preisler
Jan 1, 1984·Cancer Investigation·K M Sullivan, R Storb
May 1, 1989·The American Journal of the Medical Sciences·W R VoglerD S Gordon
Nov 1, 1989·Mayo Clinic Proceedings·K P WindebankE O Burgert
Jul 18, 1986·Cell·R RossD F Bowen-Pope
Jan 1, 1990·Critical Reviews in Oncology/hematology·R E SmithE J Szabo
Nov 1, 1988·American Journal of Hematology·R E SmithE J Szabo
Jan 1, 1982·Journal of Cellular Physiology. Supplement·K G Blume, S J Forman
Jan 1, 1989·British Journal of Haematology·I DokalJ M Goldman
Jul 1, 1983·The Journal of Pediatrics·C BrovallC I Civin
Sep 1, 1984·Cancer·F CervantesC Rozman
May 1, 1991·European Journal of Haematology·H Hasselbalch, I Lisse
Apr 1, 1990·European Journal of Haematology·B HertensteinH Heimpel
Jan 1, 1983·Immunological Reviews·R Storb, E D Thomas
Jul 1, 1984·Scandinavian Journal of Haematology·J ThieleA Georgii

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.